Similar articles

• Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.

  Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Bruchovsky N, et al. Mol Urol. 2000 Fall;4(3):191-9;discussion 201. Mol Urol. 2000. PMID: 11062374 Clinical Trial.
• Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.

  Kirollos MM. Kirollos MM. Eur Urol. 2009 Feb;55(2):e40-2; author reply e45-6. doi: 10.1016/j.eururo.2008.08.039. Epub 2008 Aug 24. Eur Urol. 2009. PMID: 18760526 No abstract available.
• Endocrine treatment of prostate cancer.

  Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
• The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.

  Cherrier MM, Rose AL, Higano C. Cherrier MM, et al. J Urol. 2003 Nov;170(5):1808-11. doi: 10.1097/01.ju.0000091640.59812.83. J Urol. 2003. PMID: 14532781 Clinical Trial.
• Managing prostate cancer: the role of hormone therapy.

  Ramirez ML, Keane TE, Evans CP. Ramirez ML, et al. Can J Urol. 2007 Dec;14 Suppl 1:10-8. Can J Urol. 2007. PMID: 18163939 Review.